Abstract

Anidulafungin: a new addition to the antifungal armamentarium

Author(s): John Mohr and Luis Ostrosky-Zeichner

Invasive fungal infections continue to be associated with high rates of morbidity and mortality, primarily in the immunocompromised hosts. Candida and Aspergillus are the most common causes of invasive fungal disease; however, other fungi can also cause disease in humans. Current therapeutic options for the management of invasive fungal infections include the polyenes, triazoles and echinocandins. Anidulafungin is a new echinocandin antifungal drug with a favorable toxicity profile and minimal drug–drug interactions that has activity against Aspergillus and Candida, including azole-resistant strains.